Agree Realty Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joel N. Agree
- Full Time Employees
- 90
- Sector
- Real Estate
- Industry
- REIT - Retail
- Address
- 32301 Woodward Avenue Royal Oak MI United States of America 48304
- IPO Date
- Apr 15, 1994
- CIK
- 0000917251
- Website
- agreerealty.com
- Similar Companies
- Business
- Agree Realty Corporation (NYSE: ADC), a fully integrated, self-administered and self-managed real estate investment trust founded in 1971 and headquartered in Royal Oak, Michigan, acquires, develops, owns and manages single-tenant retail properties net leased on a long-term basis primarily to investment-grade national and regional omni-channel retailers including Walmart, Advance Auto Parts, Dollar General, AutoZone, Gerber Collision, CVS, Burlington, Dollar Tree, Best Buy, Academy Sports, and Academy Sports; as of September 30, 2025, the portfolio comprises 2,603 properties containing approximately 54 million square feet of gross leasable area located across all 50 U.S. states, with 67% of annualized base rents derived from investment-grade tenants and 10.9% from ground leases. The company operates through acquisition, ground-up development, and its Developer Funding Platform, targeting properties in 28 retail sectors with a focus on stable, fee-simple ownership and weighted-average lease terms exceeding 10 years. In 2024, Agree Realty executed $951 million in total real estate investments including $867 million in 242 acquisitions at a 7.5% weighted-average cap rate (73.3% investment-grade in Q4), raised approximately $1.1 billion in forward equity through public offerings and its at-the-market program, closed a $350 million 5.5-year delayed draw term loan in November 2025, and strengthened liquidity to over $2.0 billion with no material debt maturities until 2028; for 2025, it projects $1.1 billion to $1.3 billion in investment volume representing a 26% increase at the midpoint.
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
If I Retired Today, I'd Buy These 2 Income Machines Before Anything Else
The Portfolio That Pays All Your Car Repairs For Life
Agree Realty Declares Monthly Common and Preferred Dividends
The REIT Strategy I Would Use To Retire Today
The 12.9% Monthly Dividend That Quietly Eats Your Portfolio
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
5 Safe Monthly Pay Dividend Stocks Boomers Love in July
My 5 Greatest REIT Winners Of All Time
ADC Therapeutics Announces New Employee Inducement Grant
Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information
Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma